AstraZeneca has divested global commercial rights to a total of five hypertension drugs to Atnahs Pharma for a consideration of $350m.

The divested medicines comprise Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol and chlorthalidone combination), Zestril (lisinopril) and Zestoretic (lisinopril and hydrochlorothiazide combination).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Inderal is a beta-blocker indicated to treat hypertension, tremors, angina and arrhythmias among other heart or circulatory conditions, but can also be used to reduce the severity and frequency of migraine.

Beta-blocker Tenormin is used for hypertension, arrhythmias and angina treatment, as well as to lower the risk of death after a heart attack.

Meanwhile, Tenoretic uses a combination of beta-blocker and diuretic (chlorthalidone) for the treatment of high blood pressure.

Zestril is designed as an angiotensin-converting enzyme (ACE) inhibitor to treat hypertension, congestive heart failure, diabetic-related conditions and hypertensive renal disease. It may also help improve survival after a heart attack.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Zestoretic is an ACE inhibitor and diuretic (hydrochlorothiazide), used to treat hypertension.

AstraZeneca signed an agreement to sell the drugs to Atnahs Pharma in January. The deal does not include the US and India rights previously sold.

Furthermore, AstraZeneca will retain the rights in Japan.

In 2018, the five medicines together generated $132m in annual sales in the markets covered by this agreement.

AstraZeneca BioPharmaceuticals executive vice-president Ruud Dobber said: “These are important established medicines and the divestment to Atnahs ensures they will continue to be available to patients.

“This transaction supports our strategy to realise value from our portfolio of non-core mature brands, enabling further investment in new medicines.”

In addition to the $350m instalment, AstraZeneca is also eligible for sales-contingent payments of up to $40m between 2020 and 2022.

Last month, AstraZeneca signed an agreement to sub-license Movantik’s global rights, except in Europe, Canada and Israel, to RedHill Biopharma.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now